Literature DB >> 17683504

Predictive factors for platelet increase after partial splenic embolization in liver cirrhosis patients.

Hiromitsu Hayashi1, Toru Beppu, Toshiro Masuda, Takao Mizumoto, Masashi Takahashi, Takatoshi Ishiko, Hiroshi Takamori, Keiichiro Kanemitsu, Masahiko Hirota, Hideo Baba.   

Abstract

BACKGROUND AND AIM: Partial splenic embolization (PSE) is often performed for improving thrombocytopenia in cirrhotic patients. We investigated the largely unclear predictive factors for platelet increase at both 1 month and 1 year after PSE.
METHODS: Aimed at increasing the platelet count, PSE was performed in 42 cirrhotic patients with thrombocytopenia (platelets < 80 x 10(4)/mL) caused by hypersplenism. The clinical data were analyzed to clarify the predictive factors for platelet increase at 1 month (n = 42) and 1 year (n = 38) after PSE.
RESULTS: The mean splenic infarction ratio was 76.7% +/- 11.2%. The platelet count increased to 259% +/- 112% and 228% +/- 75% of the pretreatment values at 1 month and at 1 year after PSE, respectively. Stepwise multiple linear regression analysis showed that the infarcted splenic volume had a positive independent association with the increase in platelet count at both 1 month (P = 0.00004) and 1 year (P = 0.005) after PSE (increase in platelet count (x10(4)/mL): at 1 month = 0.752 + 0.018 x infarcted splenic volume (mL), R(2) = 0.344; at 1 year = 2.19 + 0.01 x infarcted splenic volume (mL), R(2) = 0.203). Receiver operating characteristic analysis yielded a cut-off value of 388 mL of infarcted splenic volume for achieving an increase of 5.0-8.0 x 10(4)/mL in platelet count at 1 year.
CONCLUSIONS: PSE can reduce the platelet pool and induce an increase in platelet count. This increase is greatly dependent on the infarcted splenic volume.

Entities:  

Mesh:

Year:  2007        PMID: 17683504     DOI: 10.1111/j.1440-1746.2007.05090.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  13 in total

1.  Predictive factors for platelet count after laparoscopic splenectomy in cirrhotic patients.

Authors:  Daisuke Yoshida; Yoshihiro Nagao; Morimasa Tomikawa; Hirofumi Kawanaka; Tomohiko Akahoshi; Nao Kinjo; Hideo Uehara; Naotaka Hashimoto; Makoto Hashizume; Yoshihiko Maehara
Journal:  Hepatol Int       Date:  2011-09-30       Impact factor: 6.047

2.  Partial splenic embolization for thrombocytopenia in liver cirrhosis: predictive factors for platelet increment and risk factors for major complications.

Authors:  Mingyue Cai; Wensou Huang; Chaoshuang Lin; Zhengran Li; Jiesheng Qian; Mingsheng Huang; Zhaolin Zeng; Jingjun Huang; Hong Shan; Kangshun Zhu
Journal:  Eur Radiol       Date:  2015-05-23       Impact factor: 5.315

Review 3.  Treatment modalities for hypersplenism in liver transplant recipients with recurrent hepatitis C.

Authors:  Lena Sibulesky; Justin-H Nguyen; Ricardo Paz-Fumagalli; C-Burcin Taner; Rolland-C Dickson
Journal:  World J Gastroenterol       Date:  2009-10-28       Impact factor: 5.742

Review 4.  Partial splenic artery embolization in cirrhotic patients.

Authors:  Tyson A Hadduck; Justin P McWilliams
Journal:  World J Radiol       Date:  2014-05-28

5.  Therapeutic factors considered according to the preoperative splenic volume for a prolonged increase in platelet count after partial splenic embolization for liver cirrhosis.

Authors:  Hiromitsu Hayashi; Toru Beppu; Kazutoshi Okabe; Toshiro Masuda; Hirohisa Okabe; Takatoshi Ishiko; Hideo Baba
Journal:  J Gastroenterol       Date:  2010-01-05       Impact factor: 7.527

Review 6.  Management of thrombocytopenia due to liver cirrhosis: a review.

Authors:  Hiromitsu Hayashi; Toru Beppu; Ken Shirabe; Yoshihiko Maehara; Hideo Baba
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

7.  Telaprevir-based triple therapy following partial splenic arterial embolization for chronic hepatitis C with thrombocytopenia can reduce carcinogenesis and improve hepatic function reserve.

Authors:  Toru Ishikawa; Satoshi Abe; Yuichi Kojima; Ryoko Horigome; Tomoe Sano; Akito Iwanaga; Keiichi Seki; Terasu Honma; Toshiaki Yoshida
Journal:  Exp Ther Med       Date:  2015-08-07       Impact factor: 2.447

8.  Hypersplenism in liver disease and SLE revisited: current evidence supports an active rather than passive process.

Authors:  John M Gemery; Andrew R Forauer; Anne M Silas; Eric K Hoffer
Journal:  BMC Hematol       Date:  2016-02-09

9.  Outcomes of partial splenic embolization in patients with massive splenomegaly due to idiopathic portal hypertension.

Authors:  Omer Ozturk; Gonca Eldem; Bora Peynircioglu; Taylan Kav; Aysegul Görmez; Barbaros Erhan Cil; Ferhun Balkancı; Cenk Sokmensuer; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2016-11-21       Impact factor: 5.742

10.  Comparison of three embolic materials at partial splenic artery embolization for hypersplenism: clinical, laboratory, and radiological outcomes.

Authors:  Mohamed M A Zaitoun; Mohammad Abd Alkhalik Basha; Saeed Bakry Elsayed; Dalia Salah El Deen; Nahla A Zaitoun; Husain Alturkistani; Alaa A Farag; Hassan Abdelsalam; Hossam A El-Kenawy; Nader E M Mahmoud; Nader Ali Alayouty; Ibrahim M Eladl; Shahenda Shahin; Mohamed-Karji Almarzooqi; Ali M Hendi; Ahmad El-Morsy; Ali Hassan Elmokadem
Journal:  Insights Imaging       Date:  2021-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.